{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:28:56Z","timestamp":1793053736507,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.euo.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:01:40Z","timestamp":1785456100000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk-adapted Omission of Systematic Cores in PI-RADS 3 Lesions Based on Prostate-specific Antigen Density, Biopsy Route, and Targeted Core Number: A Multicentre Cohort Study"],"prefix":"10.1016","author":[{"given":"Bogdan Adrian","family":"Buhas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Mjaess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Diamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Uleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Abou Chakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea Bogdan","family":"Borz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Crisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Baudewyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teddy","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Jeglinschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-5364","authenticated-orcid":false,"given":"Mihaela","family":"Iancu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.07.003_b0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging \u2013 reporting and data system: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21037\/tau.2017.12.31","article-title":"MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?","volume":"7","author":"Schoots","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.urology.2022.01.020","article-title":"Practice-level variation in the decision to biopsy prostate imaging-reporting and data system 3 lesions in favorable-risk prostate cancer patients","volume":"164","author":"Versalle","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.07.003_b0025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","article-title":"Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Maggi","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.07.003_b0030","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.07.003_b0035","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.07.003_b0040","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.eururo.2019.04.043","article-title":"Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer: a systematic review and meta-analysis","volume":"76","author":"Kasivisvanathan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0045","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euo.2026.07.003_b0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2014.10.026","article-title":"Detection of clinically significant prostate cancer using magnetic resonance imaging\u2013ultrasound fusion targeted biopsy: a systematic review","volume":"68","author":"Valerio","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/jcm9010225","article-title":"Assessment of the minimal targeted biopsy core number per MRI lesion for improving prostate cancer grading prediction","volume":"9","author":"Ploussard","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2026.07.003_b0060","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouvi\u00e8re","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.07.003_b0065","unstructured":"European Association of Urology. EAU Guidelines on Prostate Cancer. https:\/\/uroweb.org\/guidelines\/prostate-cancer. Accessed April 8, 2026."},{"key":"10.1016\/j.euo.2026.07.003_b0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12894-025-01986-2","article-title":"To biopsy or not biopsy, that is the question - PI-RADS 3 prostate lesions - validation of clinical and radiological parameters for biopsy decision-making","volume":"25","author":"Franz","year":"2025","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41391-024-00872-6","article-title":"Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions","volume":"28","author":"Mjaess","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.07.003_b0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/pros.24840","article-title":"PSA density and lesion volume: key factors in avoiding unnecessary biopsies for PI-RADS 3 lesions","volume":"85","author":"Ayranci","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2026.07.003_b0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41391-022-00549-y","article-title":"PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer","volume":"26","author":"Frisbie","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.07.003_b0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/jcm12010156","article-title":"Predictors of clinically significant prostate cancer in patients with PIRADS Categories 3\u20135 undergoing magnetic resonance imaging-ultrasound fusion biopsy of the prostate","volume":"12","author":"Szempli\u0144ski","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2026.07.003_b0095","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2013.03.030","article-title":"Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group","volume":"64","author":"Moore","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0100","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2026.07.003_b0105","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/sim.7273","article-title":"Firth\u2019s logistic regression with rare events: accurate effect estimates and predictions?","volume":"36","author":"Puhr","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2026.07.003_b0110","unstructured":"CRAN. Package logistf. https:\/\/cran.r-project.org\/web\/packages\/logistf\/index.html. Accessed January 4, 2026."},{"key":"10.1016\/j.euo.2026.07.003_b0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bju.14017","article-title":"Prospective comparison of transperineal magnetic resonance imaging\/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-na\u00efve patients","volume":"121","author":"Borkowetz","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.07.003_b0120","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/cncr.34355","article-title":"Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions","volume":"128","author":"Fang","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.07.003_b0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","article-title":"Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling","volume":"82","author":"Brisbane","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/CH-189407","article-title":"Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting","volume":"71","author":"Schlenker","year":"2019","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.euo.2026.07.003_b0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.07.003_b0140","doi-asserted-by":"crossref","unstructured":"Quarta L, Pellegrino F, Stabile A, et al. Does the accuracy of prostate-specific antigen density in identifying clinically significant prostate cancer change with prostate volume? Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2025.10.005.","DOI":"10.1016\/j.euf.2025.10.005"},{"key":"10.1016\/j.euo.2026.07.003_b0145","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1097\/JS9.0000000000003269","article-title":"The role of apparent diffusion coefficient values in diagnosing prostate cancer for patients with equivocal PI-RADS 3 lesions: a multicenter retrospective study","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.euo.2026.07.003_b0150","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.07.003_b0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.eururo.2024.02.003","article-title":"Does overgrading on targeted biopsy of magnetic resonance imaging-visible lesions in prostate cancer lead to overtreatment?","volume":"86","author":"Baboudjian","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0160","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41391-024-00904-1","article-title":"Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS \u2265 3 lesions-an EAU-YAU study enhancing prostate cancer detection","volume":"28","author":"Zattoni","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.07.003_b0165","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1038\/s41598-022-10859-9","article-title":"Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate","volume":"12","author":"Boschheidgen","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2026.07.003_b0170","doi-asserted-by":"crossref","unstructured":"Buhas BA, Gregoris A, Iancu M, et al. Comparative Impact of Elastic magnetic resonance imaging-transrectal ultrasound Fusion Biopsy on Concordance of Detection of Clinically Significant Prostate Cancer by International Society of Urological Pathology Grade in Biopsy-na\u00efve Men with prostate-specific antigen \u226420 ng\/ml and cT1-2 Disease. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/J.EUO.2025.09.001.","DOI":"10.1016\/j.euo.2025.09.001"},{"key":"10.1016\/j.euo.2026.07.003_b0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging\u2013targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0180","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.euo.2024.01.019","article-title":"Transperineal versus transrectal magnetic resonance imaging\u2013targeted Biopsies for prostate cancer diagnosis: final results of the randomized PERFECT trial (CCAFU-PR1)","volume":"7","author":"Ploussard","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.07.003_b0185","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00345-024-05245-1","article-title":"Transrectal versus transperineal prostate fusion biopsy: a pair-matched analysis to evaluate accuracy and complications","volume":"42","author":"Oderda","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0190","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.euf.2024.03.003","article-title":"Transperineal or transrectal magnetic resonance imaging-targeted biopsy for prostate cancer detection","volume":"10","author":"Diamand","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.07.003_b0195","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2022.07.006","article-title":"An magnetic resonance imaging-directed targeted-plus-perilesional biopsy approach for prostate cancer diagnosis: \u201cless is more.","volume":"43","author":"Hagens","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.07.003_b0200","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41391-022-00620-8","article-title":"Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling","volume":"26","author":"Noujeim","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.07.003_b0205","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/JU.0000000000004863","article-title":"Comprehensive evaluation of targeted and perilesional biopsy in biopsy-na\u00efve patients with prostate positive magnetic resonance imaging: PERI-PRO noninferiority randomized controlled trial","volume":"215","author":"Deng","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0210","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00345-024-05000-6","article-title":"Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study","volume":"42","author":"Duwe","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0215","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bju.70027","article-title":"Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history","volume":"137","author":"Cannoletta","year":"2026","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.07.003_b0220","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00345-023-04382-3","article-title":"Role of targeted biopsy, perilesional biopsy, and random biopsy in prostate cancer diagnosis by mpMRI\/transrectal ultrasonography fusion biopsy","volume":"41","author":"Novara","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.07.003_b0225","doi-asserted-by":"crossref","unstructured":"Baboudjian M, Uleri A, Anract J, et al. Targeted, perilesional, and distant biopsies in prostate cancer. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2026.02.006.","DOI":"10.1016\/j.euo.2026.02.006"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:01:45Z","timestamp":1785456105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"alternative-id":["S2588931126001938"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.07.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-adapted Omission of Systematic Cores in PI-RADS 3 Lesions Based on Prostate-specific Antigen Density, Biopsy Route, and Targeted Core Number: A Multicentre Cohort Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}